Biohaven Ltd. BHVN
i
Market datapartial · fetched 2026-11-13T19:12:10.672Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T19:12:08.073730517Z
FundamentalsAlpha Vantage · unavailable
Biohaven Ltd. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 15.78 | 104.2% | 16.0% | 12.48 | 87.6% | 10.9% |
| 25Δ | 15.01 | 83.7% | 10.6% | 12.76 | 87.3% | 9.3% |
| 30Δ | 14.77 | 82.3% | 9.3% | 13.03 | 87.0% | 7.9% |
| 35Δ | 14.54 | 81.1% | 8.1% | 13.25 | 86.8% | 7.0% |
| 40Δ | 14.30 | 80.0% | 6.9% | 13.46 | 86.7% | 6.2% |
| 45Δ | 14.07 | 78.8% | 5.6% | 13.67 | 86.6% | 5.3% |
| 50Δ | 13.79 | 83.7% | 4.9% | 13.88 | 86.5% | 4.5% |
| 55Δ | 13.50 | 91.3% | 4.5% | 14.11 | 87.2% | 3.8% |
| 60Δ | 13.21 | 98.8% | 4.0% | 14.37 | 88.9% | 3.3% |
| 65Δ | 12.91 | 106.3% | 3.6% | 14.63 | 90.7% | 2.7% |
| 70Δ | 12.62 | 113.9% | 3.1% | 14.89 | 92.5% | 2.2% |
| 75Δ | 12.33 | 121.4% | 2.7% | |||
| 80Δ | 12.03 | 129.0% | 2.2% | |||
20Δ
- Pseudo strike
- 15.78
- IV
- 104.2%
- B/E move
- 16.0%
- Pseudo strike
- 12.48
- IV
- 87.6%
- B/E move
- 10.9%
25Δ
- Pseudo strike
- 15.01
- IV
- 83.7%
- B/E move
- 10.6%
- Pseudo strike
- 12.76
- IV
- 87.3%
- B/E move
- 9.3%
30Δ
- Pseudo strike
- 14.77
- IV
- 82.3%
- B/E move
- 9.3%
- Pseudo strike
- 13.03
- IV
- 87.0%
- B/E move
- 7.9%
35Δ
- Pseudo strike
- 14.54
- IV
- 81.1%
- B/E move
- 8.1%
- Pseudo strike
- 13.25
- IV
- 86.8%
- B/E move
- 7.0%
40Δ
- Pseudo strike
- 14.30
- IV
- 80.0%
- B/E move
- 6.9%
- Pseudo strike
- 13.46
- IV
- 86.7%
- B/E move
- 6.2%
45Δ
- Pseudo strike
- 14.07
- IV
- 78.8%
- B/E move
- 5.6%
- Pseudo strike
- 13.67
- IV
- 86.6%
- B/E move
- 5.3%
50Δ
- Pseudo strike
- 13.79
- IV
- 83.7%
- B/E move
- 4.9%
- Pseudo strike
- 13.88
- IV
- 86.5%
- B/E move
- 4.5%
55Δ
- Pseudo strike
- 13.50
- IV
- 91.3%
- B/E move
- 4.5%
- Pseudo strike
- 14.11
- IV
- 87.2%
- B/E move
- 3.8%
60Δ
- Pseudo strike
- 13.21
- IV
- 98.8%
- B/E move
- 4.0%
- Pseudo strike
- 14.37
- IV
- 88.9%
- B/E move
- 3.3%
65Δ
- Pseudo strike
- 12.91
- IV
- 106.3%
- B/E move
- 3.6%
- Pseudo strike
- 14.63
- IV
- 90.7%
- B/E move
- 2.7%
70Δ
- Pseudo strike
- 12.62
- IV
- 113.9%
- B/E move
- 3.1%
- Pseudo strike
- 14.89
- IV
- 92.5%
- B/E move
- 2.2%
75Δ
- Pseudo strike
- 12.33
- IV
- 121.4%
- B/E move
- 2.7%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 12.03
- IV
- 129.0%
- B/E move
- 2.2%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 92.70% | |
| 94.86% | |
| 92.79% | |
| 91.10% | |
| 90.83% | |
| 93.07% | |
| 92.91% | |
| 78.05% | |
| 92.72% | |
| 88.53% |
Biotechnology
BLTE
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular…
More →BMEA
Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically…
More →BMRN
BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San…
More →BNTC
Description unavailable
More →BNTX
Description unavailable
More →BYSI
BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered…
More →